Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, elaborates on how certain patients responded to the updated treatment regimen.
Although patients with both high-risk myelodysplastic syndrome (MDS) and mixed phenotype acute leukemia (MPAL) made up a small portion of the study, this group's composite complete response rate was 100%. Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, explains the takeaways from this result.
Transcript
What can we learn from the patients with MDS and MPAL in this study?
I think that there's a lot of push in the MDS/AML [acute myeloid leukemia] field to better treat the high-risk MDS patients. There's a series of new diagnostic classification schemes that have come out in the last year that suggests that some of these MDS patients that are in this high-risk category are really prone to progressing to acute myeloid leukemia. Our approach has been that, for those patients, a treatment with an AML-like regimen seems to be really useful for those patients.
The biggest takeaway from those smaller subsets is that, one, the patients with high-risk MDS—and really the patients that we're talking about there are the ones that we're really concerned are going to progress to an aggressive acute myeloid leukemia quickly from that slightly more indolent, high-risk MBS phase—those patients seem to benefit from treatment with an AML-like regimen upfront, and that's why we included them in this study.
Similarly, mixed phenotype acute leukemia is something that isn't very well categorized in terms of how to treat it. It's more rare than either AML or MDS by itself. We still struggle sometimes with what's the best way to treat these patients, so we felt strongly about including those patients in this clinical trial to learn better about how we can treat them more effectively.
The other caveat to mention is mixed phenotype acute leukemia is really broken down into those that have more of a lymphoid predominant or more of a myeloid predominant. For these patients, these have more of a myeloid predominance leukemia clone, so for those patients, I think our data would suggest this is a really effective regimen for those people.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
TP53-Mutated MDS/AML Posttransplant Treatment Gaps
April 11th 2024The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant vs those who did not.
Read More